US Patent 9,265,784: Neratinib and Capecitabine Combination Patent Landscape

US Patent 9,265,784 protects methods of treating ErbB-2-positive metastatic breast cancer with the combination of neratinib and capecitabine. Its strongest protection is directed to orally administered combination regimens, particularly 21-day cycles using continuous neratinib and scheduled capecitabine. The patent does not broadly cover neratinib monotherapy, all HER2-positive cancers, or every use of capecitabine with an HER2-directed agent.

The patent’s principal commercial relevance is Nerlynx, Puma Biotechnology’s oral neratinib product. The claimed combination is clinically associated with the NALA regimen, in which neratinib is administered with capecitabine for advanced or metastatic HER2-positive breast cancer.

What does US Patent 9,265,784 cover?

US Patent 9,265,784 covers a treatment method requiring two active ingredients:

Neratinib.
Capecitabine.

The independent claims require treatment of an ErbB-2-positive metastatic breast cancer. Claim 1 is the broadest method claim. Claim 23 is a separate independent claim directed to a specified 21-day treatment cycle.

Patent element	Claim requirement
Disease	ErbB-2-positive metastatic breast cancer
Primary drug	Neratinib
Combination drug	Capecitabine
Route	Oral administration in dependent claims and claim 23
Timing	Concurrent, sequential, or simultaneous under dependent claims
Broad dosing	Neratinib at least 40 mg/day; capecitabine about 1,250 to 3,000 mg/day
Narrow regimen	Neratinib at least 240 mg/day continuously
Cycle structure	21-day cycles
Capecitabine schedule	Days 1 to 14 under claim 23; days 1 and 14 under claim 18
Treatment duration	Three to six capecitabine cycles; approximately 24 weeks in claim 22

The claims are method-of-treatment claims. They do not claim neratinib as a chemical compound, capecitabine as a chemical compound, a tablet formulation, or a manufacturing process.

What is the claim structure of US 9,265,784?

Claim 1: broad combination-treatment claim

Claim 1 requires administering neratinib and capecitabine to a subject with ErbB-2-positive metastatic breast cancer. It does not impose a specific dose, route, sequence, cycle length, or treatment duration.

A potentially infringing treatment generally must satisfy all material limitations:

The patient has the claimed ErbB-2-positive metastatic breast cancer.
Neratinib is administered.
Capecitabine is administered.
The two drugs are used as a treatment combination.

The claim does not expressly require that both drugs be administered on the same day. Dependent claim 5 confirms that the patent contemplates concurrent, sequential, or simultaneous administration.

Claims 2 and 3: disease status and subtherapeutic dosing

Claim 2 adds locally advanced breast cancer. Because it depends on claim 1, it also incorporates claim 1’s metastatic-breast-cancer limitation. That creates a potential claim-construction issue because “locally advanced” and “metastatic” can describe different disease stages. The claim may be interpreted as covering patients whose disease is both locally advanced and metastatic, rather than all locally advanced disease.

Claim 3 covers regimens in which one or both drugs are administered in a subtherapeutically effective amount. This language expands the dosing flexibility but creates an evidentiary issue. A patent owner would need to establish what makes a dose “subtherapeutically effective” in the relevant clinical context.

Claims 4 to 7: route, timing, and unit doses

Claims 4 through 7 address:

Oral administration.
Concurrent, sequential, or simultaneous dosing.
Neratinib in a unit dose.
Capecitabine in a unit dose.

These claims are narrower than claim 1 but may be important for commercial products because Nerlynx and Xeloda or generic capecitabine are orally administered products.

Claims 8 to 11: capecitabine dose and cycle duration

Claims 8 through 11 define capecitabine dosing and treatment cycles:

About 1,250 to 3,000 mg daily.
Administration at least once during 21 days.
Three to six cycles.
Each cycle lasting 21 days.

Claim 11 supplies the 21-day cycle definition for claim 10. These claims could cover a range of clinical protocols, but the “about” language introduces ordinary patent-construction questions concerning the permissible numerical range.

Claims 12 to 17: neratinib dosing

These claims define escalating minimum neratinib doses:

At least 40 mg/day under claim 12.
At least 120 mg/day under claim 13.
At least 240 mg/day under claim 14.
Daily or at least once-daily dosing under claims 15 and 16.
Administration for at least two continuous weeks under claim 17.

The dependent structure is important. Claim 13 depends on claim 11, not directly on claim 12. Claim 14 depends on claim 12. As written, claim 13 combines the 120 mg/day requirement with the limitations inherited from claims 11 and 1, while claim 14 combines the 240 mg/day requirement with claims 12 and 1.

Claim 18: high-value regimen claim

Claim 18 is directed to:

Neratinib at least 240 mg/day continuously.
Capecitabine at least 1,500 mg/day.
Capecitabine administered on days 1 and 14 of each 21-day cycle.

This claim is materially narrower than claim 1 but more operationally significant. A product or clinical protocol using continuous neratinib at the approved 240 mg daily dose and capecitabine on the specified schedule would be a direct target for infringement analysis.

Claims 19 to 22: sequencing and duration

Claims 19 through 21 cover:

Neratinib before capecitabine.
Neratinib after capecitabine.
Simultaneous administration.

Claim 22 covers discontinuing capecitabine after approximately 24 weeks. It does not necessarily require discontinuing neratinib at the same time.

Claim 23: independent 21-day-cycle claim

Claim 23 independently requires:

A 21-day treatment cycle.
Oral neratinib beginning on day 1.
At least one unit dose of neratinib daily.
Oral capecitabine on days 1 through 14.

Unlike claim 18, claim 23 does not state a minimum neratinib or capecitabine dose. It also uses a days-1-through-14 capecitabine schedule rather than the days-1-and-14 schedule in claim 18.

Claim 23 is therefore a potentially important fallback claim. A generic or competitor could avoid claim 18 by changing dose or capecitabine timing but still face claim 23 if it uses the same oral 21-day-cycle structure.

When does US Patent 9,265,784 expire?

The patent has a statutory expiration date in December 2030 based on the underlying PCT and US application chronology. Public patent records identify December 1, 2030, as the expected expiration date for the patent family, subject to any applicable patent-term adjustment or later correction in the official USPTO record.[1]

Event	Date or status
Earliest priority	December 1, 2009
International filing	December 1, 2010
US grant	February 23, 2016
Patent number	US 9,265,784 B2
Expected statutory expiration	December 1, 2030
Patent type	Method-of-treatment patent
Primary subject	Neratinib plus capecitabine

The patent’s remaining commercial value depends on whether the patent is still enforceable, whether any terminal disclaimer affects its term, and whether the listed claims survive validity challenges. Patent expiration does not eliminate other neratinib patents that may cover composition, formulation, dosing, or other indications.

What is the Orange Book status of US 9,265,784?

Neratinib is marketed in the United States as Nerlynx tablets under FDA-approved labeling for extended adjuvant treatment of early-stage HER2-positive breast cancer and, in a separate indication, for advanced or metastatic HER2-positive breast cancer following two or more prior anti-HER2-based regimens in the metastatic setting.[2]

The Orange Book is the principal FDA publication for patents submitted by an NDA holder for approved drug products. Orange Book listing must be assessed by product, NDA, dosage form, and patent-use code. A method patent may be listed only if it covers an approved method of using the drug and satisfies FDA listing requirements.[3]

US 9,265,784 is commercially relevant to the Nerlynx metastatic-breast-cancer indication because its claims cover neratinib in combination with capecitabine. The relevant regulatory question is whether the patent is listed against the NDA with a use code covering that combination treatment. Orange Book listing does not itself establish patent validity or infringement.

The FDA label for Nerlynx identifies neratinib in combination with capecitabine as an approved treatment option for advanced or metastatic HER2-positive breast cancer after at least two prior anti-HER2-based regimens.[2] The label also identifies the standard Nerlynx dose as 240 mg orally once daily with food, subject to dose modifications.

What clinical regimen does the patent protect?

The patent’s claims overlap with the clinical regimen used in advanced HER2-positive breast cancer. The NALA trial evaluated neratinib plus capecitabine against lapatinib plus capecitabine in patients with metastatic HER2-positive breast cancer who had received at least two prior HER2-directed regimens.[4]

The practical overlap is strongest for:

Neratinib 240 mg orally once daily.
Capecitabine administered during repeated 21-day cycles.
Oral administration of both products.
Treatment in advanced or metastatic HER2-positive disease.

The patent is not limited to the exact FDA-labeled patient population. Claim 1 does not expressly require two prior anti-HER2 regimens, and several dependent claims do not require the NALA trial’s full eligibility criteria.

How strong is the patent estate for neratinib and capecitabine?

The patent has moderate-to-strong value for the specific combination, but weaker protection against design-around strategies.

Strengths

Claim 1 is broad within the combination field. It does not require a particular dose or schedule.
Claim 23 independently captures an oral 21-day-cycle regimen.
Claim 18 targets a clinically recognizable high-dose neratinib regimen.
The claims cover sequential as well as simultaneous administration.
The patent aligns with an FDA-approved metastatic-breast-cancer use of Nerlynx.

Vulnerabilities

The combination of neratinib and capecitabine may face obviousness arguments based on earlier clinical and pharmacological disclosures concerning HER2 inhibitors and fluoropyrimidines.
“Subtherapeutically effective amount” may be challenged as indefinite or insufficiently objective, depending on the specification and prosecution history.
“About” dose ranges may produce disputes over the numerical boundaries.
Claim 2 has a potential locally advanced-versus-metastatic inconsistency.
The patent does not control neratinib monotherapy.
It does not necessarily cover combinations with other chemotherapy agents, antibody-drug conjugates, or immunotherapies.
A competitor could seek a regimen outside the claimed cycle, dose, or sequence limitations, although claim 1 is less dependent on those details.

The commercial enforceability analysis should focus on the issued claims, the prosecution-history amendments, written-description support, cited prior art, and the precise FDA-approved use code.

What other patents protect neratinib?

Neratinib has a broader patent estate than US 9,265,784. The relevant categories include:

Patent category	Commercial subject
Compound patents	Neratinib chemical structure and related quinoline derivatives
Salt and solid-state patents	Crystalline forms, salts, and solid formulations
Formulation patents	Oral tablets, excipients, stability, and dosage forms
Treatment patents	Breast cancer, HER2-positive disease, and dosing regimens
Adverse-event management	Diarrhea prophylaxis and dose-management strategies
Combination patents	Neratinib with capecitabine or other anticancer agents
Regulatory exclusivity	NDA-based exclusivity separate from patent rights

The patent landscape must be separated into two questions:

Whether a generic can make and sell neratinib after core compound patents expire.
Whether the generic can market a product for the patented neratinib-plus-capecitabine indication.

A generic may seek a Paragraph IV certification against listed patents while using a section viii “skinny label” to omit patented uses. The commercial effect depends on whether the patented metastatic combination use is carved out of the label and whether the remaining unpatented indications support a viable launch.

Which companies are challenging the neratinib patent estate?

Publicly available regulatory and litigation information should be reviewed for each ANDA applicant and each listed Nerlynx patent. A Paragraph IV filing may remain confidential until the NDA holder receives notice and files suit. Litigation can therefore arise after the patent has already become a commercial barrier.

The principal potential challengers are generic manufacturers that develop oral neratinib tablets and seek ANDA approval. The relevant litigation issues would include:

Invalidity based on obviousness.
Lack of written description or enablement.
Indefiniteness of dose and treatment-language limitations.
Noninfringement through a label carve-out.
Whether a generic label induces use of the patented combination.
Whether the patent is properly listed for the relevant approved indication.

No biosimilar pathway applies to neratinib. Neratinib is a small-molecule drug regulated through the ANDA framework, not a biologic regulated through the abbreviated Biologics License Application pathway.

What generic entry risks exist?

Generic entry risk is likely to develop in stages.

Scenario 1: no early Paragraph IV challenge

If no ANDA applicant challenges the relevant patents, entry is constrained by the latest enforceable patent or regulatory exclusivity. The combination patent could remain relevant through December 2030.

Scenario 2: Paragraph IV litigation

An ANDA applicant may file a Paragraph IV certification alleging that the patent is invalid, unenforceable, or not infringed. A timely patent-infringement action generally triggers a 30-month FDA approval stay under the Hatch-Waxman framework, subject to statutory exceptions.[5]

Scenario 3: skinny-label launch

A generic may omit the patented neratinib-plus-capecitabine use from its labeling. The risk then shifts to induced infringement, physician prescribing behavior, pharmacy substitution, and whether the remaining approved uses are commercially sufficient.

Scenario 4: authorized generic or settlement

Puma or a successor rights holder could resolve an ANDA dispute through a license, delayed-entry agreement, authorized generic arrangement, or other settlement structure. Any settlement involving a generic launch date would require review under FTC and DOJ pharmaceutical-settlement policies.[6]

How does US 9,265,784 compare with formulation and method-of-use patents?

US 9,265,784 is a combination method patent. It differs from other patent categories in enforcement value.

Patent type	What it protects	Design-around potential
Compound patent	Neratinib molecule	Low before expiry
Formulation patent	Tablet composition or release properties	Moderate to high
Combination patent	Neratinib plus capecitabine	Moderate
Method-of-use patent	Specific cancer, patient group, or regimen	Moderate
Manufacturing patent	Process or intermediate	High if alternate process exists
Diarrhea-management patent	Prophylaxis or dose-management protocol	Moderate

The combination patent has greater relevance to an ANDA label than a manufacturing patent. It can also create prescribing and inducement exposure even if the generic tablet itself is chemically identical and designed around formulation claims.

What licensing deals affect this patent?

Neratinib was originally associated with Wyeth, which was acquired by Pfizer. Puma Biotechnology obtained rights to develop and commercialize neratinib from Pfizer and became the principal commercial sponsor of Nerlynx.[7] The licensing history is relevant because patent ownership, NDA ownership, and enforcement authority may differ across the patent family.

A license or assignment of the underlying patent does not necessarily transfer:

The NDA.
The right to sue on every patent.
Regulatory exclusivity.
Rights in foreign jurisdictions.
Rights to separate formulations or companion patents.

The patent’s chain of title should be confirmed in USPTO assignment records before relying on ownership assumptions.

What is the geographic coverage?

US 9,265,784 provides rights only in the United States. Parallel patent families may exist in:

Europe.
Canada.
Japan.
Australia.
China.
Other major pharmaceutical markets.

Foreign family members can differ materially in claim scope, validity, term, and prosecution history. A US claim covering metastatic HER2-positive breast cancer does not establish equivalent protection in Europe or other jurisdictions.

For global licensing or launch planning, the key variables are:

National-phase entry.
Granted claim scope.
Patent-term adjustments or supplementary protection certificates.
Local patent-linkage rules.
Local approval of neratinib plus capecitabine.
Availability of generic capecitabine.
Enforcement standards for medical-use claims.

Key Takeaways

US 9,265,784 protects treatment of ErbB-2-positive metastatic breast cancer using neratinib plus capecitabine.
Claim 1 is the broadest combination claim and does not require a specific dose or schedule.
Claim 18 targets continuous neratinib of at least 240 mg/day with capecitabine on days 1 and 14 of 21-day cycles.
Claim 23 independently covers oral neratinib beginning on day 1 and oral capecitabine on days 1 through 14 of a 21-day cycle.
The patent is a method-of-treatment patent, not a compound, formulation, or manufacturing patent.
The expected statutory expiration is December 1, 2030, subject to the official USPTO term record.
The patent is commercially relevant to Nerlynx’s metastatic HER2-positive breast-cancer indication.
Generic risk will depend on Orange Book listing, Paragraph IV certifications, label carve-outs, and any settlement.
No biosimilar pathway applies because neratinib is a small-molecule drug.
The principal validity risks concern obviousness, written description, enablement, indefiniteness, and the interpretation of disease-stage and dose limitations.

FAQs

Does US 9,265,784 cover Nerlynx monotherapy?

No. The claims require both neratinib and capecitabine. Neratinib monotherapy is outside the express combination limitations.

Does the patent cover every capecitabine dose used with neratinib?

Claim 1 is not dose-limited, but dependent claims impose specific dose and schedule limitations. A full infringement analysis must determine whether the accused regimen satisfies claim 1 or a narrower dependent claim.

Can a generic sell neratinib for an indication not covered by this patent?

Potentially. A generic may seek approval with a carved-out label for unpatented uses. The resulting launch would depend on the remaining patents, regulatory labeling, prescribing behavior, and induced-infringement risk.

Is claim 23 broader than claim 18?

In some respects. Claim 23 does not state minimum drug doses, but it requires oral administration and capecitabine on days 1 through 14 of a 21-day cycle. Claim 18 requires higher dose thresholds but uses the narrower days-1-and-14 schedule.

Does FDA approval prove that US 9,265,784 is valid?

No. FDA approval and Orange Book listing are regulatory events. They do not establish patent validity, enforceability, or infringement.

References

United States Patent and Trademark Office. (2016). US Patent No. 9,265,784 B2: Methods of treating cancer with neratinib and capecitabine.
U.S. Food and Drug Administration. (2023). Nerlynx (neratinib) prescribing information. Puma Biotechnology, Inc.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
Saura, C., Oliveira, M., Feng, Y. H., Dai, M. S., Chen, S. W., Hurvitz, S. A., et al. (2020). Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with two or more HER2-directed regimens: Phase III NALA trial. Journal of Clinical Oncology, 38(27), 3138-3149.
Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).
Federal Trade Commission. (2013). Agreements filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003.
Puma Biotechnology, Inc. (2024). Annual report on Form 10-K.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017		RX	Yes	Yes	9,265,784	⤷ Start Trial				USE IN COMBINATION WITH CAPECITABINE, FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR ANTI-HER2 BASED REGIMENS IN THE METASTATIC SETTING	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009279771	⤷ Start Trial
Brazil	PI0916694	⤷ Start Trial
Canada	2730715	⤷ Start Trial
China	102202667	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 9,265,784